Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...

Heavily pretreated breast cancer and non-small cell lung cancer patients with NECTIN4 gene amplification and/or polysomy demonstrated an enhanced response to zelenectide pevedotin Company to advance ...

Dec 16 (Reuters) - Merck (MRK.N), opens new tab said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several trials. The pharmaceutical giant's ...

Mark Ratain’s First Opinion piece of Feb. 4, 2025, implies that the oncologists in NCI’s Investigational Drug Branch (IDB) colluded with the drug company Exelixis to sponsor two Phase 3 studies of its ...

(Yicai) Jan. 13 -- Shares of RemeGen surged by their daily trading limit in Shanghai after the Chinese drugmaker granted US ...

After years stuck in the “doldrums,” the biopharma sector is in a “very good place” heading into the new year, analysts told ...

The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...

The deal is the second Chinese oncology pact in as many weeks for AbbVie, which also committed $175 million for a ...

Multi-year partnership with France's Servier will use Insilico's AI platform to explore novel cancer drugs Newly Hong ...